Small Cell Lung Cancer

Our Approach Has Created an Innovative Pipeline
in Targeted Radiopharmaceuticals

RYZ101 for Small Cell Lung Cancer

Lung cancer is the second most common cancer in the United States with an estimated 235,760 new diagnoses per year, of which Small Cell Lung Cancer (SCLC) represents approximately 13% patients. SCLC is distinguished from other forms of lung cancer by its rapid doubling time, high growth fraction and early manifestation of metastatic disease. Given this, very few patients are eligible for surgical treatment and cure.

We estimate that up to half of SCLC tumors overexpress SSTR2, thus representing a population subset that could be treated with RYZ101.

RayzeBio has commenced patient recruiting and enrollment in a Phase 1 trial after receiving clearance from FDA to investigate RYZ101 in first-line treatment of patients with SSTR+ extensive-stage small cell lung cancer (ES-SCLC) in combination with standard of care.

Details of the study can be found on